Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
Titel:
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
Auteur:
Wang, F. Wei, X.L. Wang, F.H. Xu, N. Shen, L. Dai, G.H. Yuan, X.L. Chen, Y. Yang, S.J. Shi, J.H. Hu, X.C. Lin, X.Y. Zhang, Q.Y. Feng, J.F. Ba, Y. Liu, Y.P. Li, W. Shu, Y.Q. Jiang, Y. Li, Q. Wang, J.W. Wu, H. Feng, H. Yao, S. Xu, R.H.